Loading stock data…
GRAL
$54.06-0.42 (-0.77%)
Market ClosedLast close May 1
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
GRAIL, Inc. in the Healthcare sector is trading at $54.06. The stock is currently 55% below its 52-week high of $118.84, remaining 19.0% below its 200-day moving average. Technical signals show neutral RSI of 62 and bullish MACD crossover, explaining why GRAL maintains its current current market pressure. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 62) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$54.06
Potential Upside
5%
Whystock Fair Value$56.76
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.16B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-15.84%
Volume
Today's trading volume
502,509
Recent News
Will Ultragenyx (RARE) Report Negative Q1 Earnings? What You Should Know
Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
A Look At GRAIL (GRAL) Valuation After New Galleri Integrations With Epic Junction And Superpower
GRAIL (GRAL) is back in focus after a run of integration deals that plug its Galleri multi cancer early detection blood test into Epic electronic health records, Junction’s diagnostic infrastructure, and Superpower’s preventive health platform. See our latest analysis for GRAIL. Those integration headlines come amid a sharp reset in sentiment, with a 1 day share price return of a 4.06% decline and a 90 day share price return of a 54.42% decline, even as the 1 year total shareholder return...
GRAIL Partners With Epic to Broaden Galleri Test Access Across US
GRAIL partners with Epic to embed its Galleri cancer test into EHRs, expanding access across nearly 450 health systems and streamlining clinical workflows nationwide.
Grail (GRAL) Rated Buy by Guggenheim on Galleri Potential
Grail Inc. (NASDAQ:GRAL) ranks among the recent spin-off companies that hedge funds are piling into. Following investor meetings with company management, Guggenheim reiterated its Buy rating and $130 price target for Grail Inc. (NASDAQ:GRAL) on March 23. The firm believes Galleri has long-term value as a broad-based multi-cancer early detection test, especially now that a […]
Block upgraded, Starbucks downgraded: Wall Street's top analyst calls
Block upgraded, Starbucks downgraded: Wall Street's top analyst calls